Growing evidence from animal and clinical studies suggests that cardiac cell therapy can restore perfusion and improve function in the ischemic/infarcted myocardium. However, cell therapy is hindered by insufficient cell numbers, inefficient cell homing and engraftment, and inadequate cellular interactions. Furthermore, the biological mechanisms and local effects of transplanted cells have not been well-elucidated. The research presented herein attempts to address some of these issues. In manuscript #1, a new subpopulation of circulating progenitor cells (CPCs), termed derived CD133+ cells, was generated from the CD133- fraction of human peripheral blood. The derived CD133+ progenitors appeared to have superior vasculogenic potential in vitro, which may prove to be beneficial in inducing vasculogenesis in ischemic tissues. Positron emission tomography (PET) with direct cell labeling and reporter gene techniques were employed to assess the fate of transplanted human CPCs in vivo at different subjects of investigation, and different stages of cell transplantation. In manuscript #2, PET imaging with 2-[18F]fluoro-2-deoxy-D-glucose (18F-FDG) direct cell labeling was used to demonstrate that collagen-based matrices improve the early homing and retention of delivered CPCs in a rat ischemic hindlimb model. This mechanism conferred by the matrix may have implications on cell therapy at the early stages after transplantation. In manuscript #3, a more efficient, stable and accurate labeling method, hexadecyl-4-[18F]fluorobenzoate (18F-HFB) direct cell labeling, was developed to quantify cell distribution of transplanted CPCs in a rat myocardial infarction model. PET imaging of 18F-HFB-CPCs revealed significant cell washout from the myocardium immediately after intramyocardial injection, with only a small proportion of transplanted CPCs remaining in the target area in the first 4 hours after delivery. In manuscript #4, human CPCs transduced with lentiviral vectors showed stable expression of PET reporter genes. This reporter gene based-cell labeling technique can be developed for noninvasive tracking cells within a bioengineered matrix by PET, while preserving cell phenotype, viability and function. These studies contribute important insights into the biology and physiology of transplanted stem cells and the ability of delivery matrices to improve transplanted cell engraftment, survival, and function. I believe with further refinement, cell expansion, tissue engineering and PET imaging could facilitate the clinical applications of cell therapies in years to come.

An increasing body of evidence points to a key role of endoplasmic reticulum (ER) stress in chronic and acute neurodegenerative diseases. Indeed, markers of ER stress are common features of neurons destined to die in these conditions. In the present study we demonstrate that PUMA, a BH3-only member of the Bcl-2 family is essential for ER stress-induced cell death. PUMA is known to be a key transcriptional target of p53, however we have found that ER stress triggers PUMA induction and cell death through a p53-independent mechanism involving instead the ER stress inducible transcription factor ATF4. Specifically, we demonstrate that ectopic expression of ATF4 sensitizes neurons to ER stress induced apoptosis, and that ATF4-deficient neurons exhibit markedly reduced levels of PUMA expression and cell death. However, chromatin immunoprecipitation experiments suggest that ATF4 does not directly regulate the PUMA promoter. Rather, we found that ATF4 induces expression of the transcription factor CHOP, and that CHOP in turn directly activates PUMA induction. Specifically, we demonstrate that CHOP binds to the PUMA promoter during ER stress and that CHOP knockdown attenuates PUMA induction and neuronal apoptosis. In summary, we have identified a key signaling pathway in ER stress induced neuronal death involving ATF4-CHOP mediated transactivation of the pro-apoptotic Bcl-2 family member PUMA. Protein aggregates and markers of ER stress response have also been observed in dying neurons in several animal models of cerebral ischemia. Therefore, to decipher the significance of the ER stress apoptotic response, we investigate the role of ATF4-CHOP signaling pathway in ischemic neuronal injury. Ischemic stroke results from a transient or permanent reduction in cerebral blood flow in the brain. In spite of much research in trying to develop therapeutic strategies, most clinical trials have failed. These failures demonstrate that effective treatments require a more complete understanding of molecular signals that lead to neuronal death. However, stroke is a complex scenario since distinct mechanisms may involve in rapid and/or delayed neuronal death. The signaling pathways regulating these mechanisms however are not fully defined. Previous studies had suggested that ER stress playing a pivotal role in post-ischemic neuronal death. Yet, the relevance of ER stress signals was not fully known in ischemic neuronal injury. Accordingly, this thesis research attempts to explore the functional role of ER stress -inducible pathway, ATF4-CHOP axis, in different models of neuronal death (delayed and excitotoxic cell death) evoked by ischemia. The data indicates that ATF4 is essential in delayed type of death in vitro. In focal ischemia model (tMCAO) ATF4 also plays a role as a mediator of death signal in vivo. However, CHOP function looks more complex, and our data did not support the role of CHOP in ischemic neuronal death.

Diss. (sammanfattning) Stockholm : Karolinska institutet, 2007. / Härtill 5 uppsatser.

Diss. (sammanfattning) Stockholm : Karolinska institutet, 2007. / Härtill 5 uppsatser.

Diss. (sammanfattning) Stockholm : Karol. inst., 2002. / Härtill 5 uppsatser.

Thesis (Ph. D.)--Uniformed Services University of the Health Sciences, 2006. / Typescript (photocopy).

Thermal imaging is a non-invasive and marker-free approach for intraoperative measurements of small temperature variations. In this work, we demonstrate the abilities of active dynamic thermal imaging for analysis of tissue perfusion state in case of cerebral ischemia. For this purpose, a NaCl irrigation is applied to the exposed cortex during hemicraniectomy. The cortical temperature changes are measured by a thermal imaging system and the thermal signal is recognized by a novel machine learning framework. Subsequent tissue heating is then approximated by a double exponential function to estimate tissue temperature decay constants. These constants allow us to characterize tissue with respect to its dynamic thermal properties. Using a Gaussian mixture model we show the correlation of these estimated parameters with infarct demarcations of post-operative CT. This novel scheme yields a standardized representation of cortical thermodynamic properties and might guide further research regarding specific intraoperative diagnostics.

Abstract There is substantial evidence on the associations between cold ambient temperature and adverse health effects. Less is known about the role of prolonged episodes of cold weather denoted as cold spells. This study assessed relations between cold spells and adverse health effects globally, and quantified and elaborated the associations between cold spells and sudden cardiac death (SCD) in northern Finland. Based on random-effects models in the meta-analyses of evidence from 9 studies around the world, cold spells were associated with increased mortality rates from all or all non-accidental causes (RR 1.10; 95% CI: 1.04–1.17), cardiovascular diseases (RR 1.11; 95% CI: 1.03–1.19), and respiratory diseases (RR 1.21; 95% CI: 0.97–1.51). Suggestive evidence of other health effects was identified. Investigating 51-years of coordinate-specific weather data at the home coordinates of autopsy-verified cases of SCD, conditional logistic regression in a case-crossover setting produced an estimate for the association between cold spells and the risk of SCD (OR 1.33; 95% CI: 1.00–1.78). A greater number of cold days preceding death increased the risk of SCD approximately 19% per day (OR 1.19; 95% CI: 1.07–1.32). The association between season-specific cold spells and SCD was strongest during autumn and winter, and lowest during spring and summer. The association was stronger for ischemic (OR 1.55; 95% CI: 1.12–2.13) than for non-ischemic SCD (OR 0.68; 95% CI: 0.32–1.45) (Q-statistic 3.85, p 0.05), confirmed by the autopsy finding. Among cases suffering ischemic SCD, the association seemed stronger in those without a prior diagnosis of ischemic heart disease than in those diagnosed during lifetime. The association seemed stronger with severe coronary stenosis (OR 1.60; 95% CI: 1.11–2.30), and weaker with moderate stenosis (OR 0.97; 95% CI: 0.37–2.55). The use of aspirin, β-blockers, and nitrates seemed to decrease the risk of ischemic SCD during cold spells. In conclusion, cold spells increased the risk of ischemic SCD, and patients without appropriate diagnosis and medications for ischemic heart disease seemed most susceptible. The results indicate that coronary stenosis plays a central role in the cold-related pathogenesis of SCD. Timely diagnosis and treatment of ischemic heart disease might reduce weather-related SCDs in a community. / Tiivistelmä Kylmän lämpötilan ja terveyshaittojen välisistä yhteyksistä on vahva tutkimusnäyttö. Vähemmän tiedetään pitkittyneiden kylmäjaksojen ja terveyshaittojen välisistä yhteyksistä. Tutkimuksessa arvioitiin kylmäjaksojen ja terveyshaittojen välisiä yhteyksiä globaalisti, ja määritettiin kylmäjaksojen ja sydänperäisen äkkikuoleman (SÄK) välisiä yhteyksiä Pohjois-Suomessa. Yhdeksän eri puolella maailmaa toteutetun tutkimuksen tulosten meta-analyysissa satunnaisvaikutusten malli osoitti yhteyden kylmäjaksojen ja kaikkien tai luonnollisien syiden (RR 1.10; 95% CI: 1.04–1.17), sydän- ja verisuonisairauksien (RR 1.11; 95% CI: 1.03–1.19), ja hengityselimistön sairauksien (RR 1.21; 95% CI: 0.97–1.51) kuolleisuuden välillä. Viitteellistä näyttöä havaittiin muista terveyshaitoista. Tutkittaessa 51-vuoden koordinaattikohtaista säätä case-crossover-asetelmassa oikeuslääketieteellisesti vahvistettujen SÄK-tapausten kotiosoitteissa, ehdollisen logistisen regression mukaan SÄK:n riski oli yhteydessä kuolemaa edeltävään kylmäjaksoon (OR 1.33; 95% CI: 1.00–1.78). Lisääntyvä kylmien päivien lukumäärä ennen kuolemaa lisäsi riskiä keskimäärin 19% päivää kohden (OR 1.19; 95% CI: 1.07–1.32). Yhteys kausikohtaisten kylmäjaksojen ja SÄK:n välillä oli vahvin syksyllä ja talvella, ja heikoin keväällä ja kesällä. Yhteys oli vahvempi kylmäjaksojen ja iskeemisen SÄK:n (OR 1.55; 95% CI: 1.12–2.13) kuin kylmäjaksojen ja ei-iskeemisen SÄK:n (OR 0.68; 95% CI: 0.32–1.45) välillä (Q-statistic 3.85, p 0.05). Iskeemisen SÄK:n kokeneilla yhteys vaikutti vahvemmalta tapauksilla joilla ei ollut aiempaa iskeemisen sydänsairauden diagnoosia, kuin tapauksilla jotka oli diagnosoitu elinaikana. Yhteys vaikutti vahvemmalta vaikea-asteisesta sepelvaltimostenoosia sairastavilla (OR 1.60; 95% CI: 1.11–2.30), kuin lievempi-asteisessa stenoosissa (OR 0.97; 95% CI: 0.37–2.55). Aspiriini, β-salpaajat, ja nitraatit vaikuttivat vähentävän iskeemisen SÄK:n riskiä kylmäjakson aikana. Yhteenvetona, kylmäjaksot lisäsivät iskeemisen SÄK:n riskiä, ja potilaat vailla iskeemisen sydänsairauden diagnoosia ja lääkityksiä vaikuttivat olevan alttiimpia kylmäjaksojen haittavaikutuksille. Tulokset viittaavat sepelvaltimostenoosin keskeiseen rooliin kylmään liittyvän SÄK:n patogeneesissä. Varhainen iskeemisen sydänsairauden diagnoosi ja siihen liittyvä sydäntä suojaava lääkitys voisivat vähentää säähän liittyviä SÄK:a.

A participação de marcadores bioquímicos na avaliação de quadros de asfixia neonatal é cada vez mais relevante. A proteína S100B tem um papel destacado nestas pesquisas. O objetivo deste estudo foi procurar destacar a importância da proteína S100B na avaliação de recém-nascidos a termo com quadros de encefalopatia hipóxico-isquêmica, assim como correlacionar com outras substâncias que também participam do processo isquêmico. Foram analisados 21 casos de recém-nascidos a termo que desenvolveram quadro de encefalopatia hipóxico-isquêmica, no período de setembro de 2003 a outubro de 2004. Realizadas coletas no 1º e 4º dia de vida e dosadas, por método imunocitoquímico, a proteína S100B e o lactato. Foi possível detectar uma correlação positiva entre as 2 substâncias, assim como, quando comparadas entre si, observou-se também significância estatística. / Biochemical markers have played an increasingly relevant role in the assessment of neonatal asphyxia. The S100B protein is particularly important in research conducted in this field. The purpose of this study was to underline the importance of S100B protein in the assessment of term newborn infants with hypoxic ischemic encephalopathy, as well as to relate it to other substances also involved in the ischemic process. An assessment was made from September 2003 to October 2004 of twenty-one term newborn infants who developed hypoxic ischemic encephalopathy. Samples were collected on the 1st and 4th day of life and S100B protein and lactate levels were calculated using the immune cytochemical method. A positive relationship was found between the 2 substances. Additionally, a comparison between the two substances showed a statistically significant correlation.

Introdução: Diversas condições clínicas podem modificar a resposta ao tratamento trombolítico no acidente vascular isquêmico agudo. O grau de comorbidade dos pacientes medido pelo Índice de Charlson, um índice que mede o grau de comorbidades clínicas em AVC, tem valor prognóstico na incapacidade pós-AVC tanto em populações com acidente vascular do tipo hemorrágico como isquêmico. Objetivo: Avaliar o efeito do grau de comorbidade aferido pelo índice de Charlson na resposta ao tratamento trombolítico no acidente vascular isquêmico e a incapacidade na alta hospitalar. Métodos: Estudo de coorte prospectivo de 96 pacientes tratados com trombólise para o acidente vascular isquêmico, avaliando o impacto das comorbidades clínicas na resposta ao tratamento trombolítico no AVC isquêmico. Os pacientes foram divididos em dois grupos, aqueles com alto ou baixo grau de comorbidades clínicas, conforme o índice de Charlson. A evolução após o tratamento foi aferida pelo escore de gravidade dos sintomas de acordo com a escala do NIHSS medido antes da infusão, imediatamente após o tratamento, 24horas e 7 dias após a trombólise. A incapacidade na alta foi avaliada pela escala modificada de Rankin sendo, considerada boa resposta a pontuação 0-1 e sua frequência comparada entre os dois grupos de pacientes. Resultados: A comparação dos escores médios do NIHSS mostraram diferenças significativas nos diferentes momentos entre os grupos de alta e baixa comorbidade (Wilk's Lambda test F (1,92) = 24.293; p< 0.001). Pacientes com índice de comorbidade baixo apresentaram redução do escore do NIHSS de 10.13 para 2.9, enquanto que no grupo com alta comorbidade, o tratamento trombolítico demostrou pouco efeito. Uma boa evolução, definida como incapacidade 0 e 1 na escala modificada de Rankin, foi observada em (73%) dos pacientes com baixo índice de comorbidade, enquanto somente (15%) dos pacientes com alto índice de comorbidade apresentaram essa evolução favorável, uma diferença clinicamente muito significativa (RR 5.62; 95% CI = 2.97 a 10.65; p< 0.001). Conclusão: A presença de comorbidades clínicas medida peloíndice de Charlson foi associada a uma menor resposta neurológica no tratamento trombolítico do AVC isquêmico e a um maior grau de incapacidade funcional na alta. / Background and purpose: Clinical comorbidities modify prognosis in haemorrhagic and ischaemic stroke. Charlson Comorbidity index is a validated and useful tool for evaluating comorbidity in stroke. In this study we evaluated the effect of clinical comorbidities as measured by Charlson Comorbidity Index in the in ischaemic stroke thrombolysis. Methods: Prospective cohort study of 96 thrombolysis treated ischaemic stroke patients. The cohort population was divided in two groups according with severity of Charlson Comorbidity Index. During study, NIHSS score was evaluated four times (pre, post, 24 hours and 7 days after thrombolysis) and lower or higher comorbidities groups were compared using repeated measures ANOVA. Response to thrombolysis in both groups was also analysed with disability modified Rankin scale. Results: We observed differences in evolution of mean NIHSS scores between higher and lower clinical comorbidity groups. Patients with low clinical comorbidities experiencing a significant reduction of NIHSS score that ranged from 10.13 to 2.9 points, while patients in the HIC group had initial NIHSS score of 14.75 and final NIHSS score of 13.78 (Wilk's Lambda test F (1,92) = 24.293; p< 0.001). Lack of response to thrombolysis had direct relation with disability at hospital discharge. Better clinical outcome, as evaluated by modified Rankin scale of 0 and 1, was markedly different between groups, with 23 (73%) versus 9 (15%) in low and high clinical comorbidities patients respectively (RR=5.62; 95%CI=2.97 to 10.65; p< 0.001). Conclusion: High level of clinical comorbidities negatively influences response to thrombolysis, attenuating treatment related reduction of stroke symptoms severity and increasing the frequency of disabled patients at discharge.